871.0000 -4.70 (-0.54%)
NSE Sep 19, 2025 15:31 PM
Volume: 232.5K
 

871.00
-0.54%
Sharekhan
Q2FY25 revenues totaling Rs. 1,201 crore, demonstrating a significant y-o-y growth rate of 20%.EBITDA stood at Rs. 236 crore, marking a remarkable y-o-y increase of 31%.
Strides Pharma Science Ltd. is trading above its 200 day SMA of 755.0
More from Strides Pharma Science Ltd.
Recommended